ACAD

ACADIA Pharmaceuticals Inc.

23.75 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ACADIA Pharmaceuticals Inc. stock is down -5.38% since 30 days ago. The next earnings date is May 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 88% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Feb 18:11 17 Jan, 2025 35.00 CALL 500 238
27 Feb 17:36 15 Mar, 2024 25.00 CALL 160 899
27 Feb 17:40 15 Mar, 2024 25.00 CALL 101 899
27 Feb 20:42 15 Mar, 2024 25.00 PUT 237 803
28 Feb 15:06 19 Apr, 2024 22.00 PUT 255 336
28 Feb 15:15 15 Mar, 2024 25.00 PUT 233 1064
28 Feb 15:21 19 Apr, 2024 22.00 PUT 4999 336
28 Feb 19:00 15 Mar, 2024 23.00 PUT 675 515
29 Feb 14:43 19 Apr, 2024 25.00 CALL 622 412
29 Feb 20:15 15 Mar, 2024 24.00 CALL 364 553

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

  • JP Morgan
    Fri Mar 1, 07:48
    buy
    confirm
  • HC Wainwright & Co.
    Wed Feb 28, 12:12
    buy
    confirm
  • Cantor Fitzgerald
    Wed Feb 28, 11:01
    buy
    confirm
  • RBC Capital
    Wed Feb 28, 09:46
    buy
    confirm
  • Mizuho
    Wed Feb 28, 08:40
    buy
    confirm
  • Needham
    Wed Feb 28, 06:21
    buy
    confirm
  • JP Morgan
    Wed Feb 7, 11:30
    buy
    confirm
  • Oppenheimer
    Mon Feb 5, 08:52
    hold
    confirm